Nostrum Labs, CEO to pay up to $50M in DOJ false claims case

DOJ building

Pharmaceuticals firm Nostrum Laboratories and its founder and chief executive officer could pay up to $50 million as part of a settlement with the Department of Justice (DOJ) addressing alleged violations of the False Claims Act by underpaying Medicaid rebates.

Nostrum and CEO Nirmal Mulye agreed to pay at least $3.8 million, with the remainder of the settlement total to be determined based on their respective financial conditions, the DOJ announced in a press release Monday. Portions of the remaining money would be split among Medicaid-participating states as part of separate settlements, according to the agency’s settlement agreement.

The total would not exceed the $50 million figure.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.